TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00952536

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Juice Plus+ with vegetable & fruit & berry capsule
Description: Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Juice Plus+ vegetable & fruit & placebo capsule
Description: Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
Study: NCT00003476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT05893667

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: analysis of inflammatory scores

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: analysis of inflammatory scores
Study: NCT00952536

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in the form of 6 capsules
Description: Daily Placebo in the form of 6 capsules (control group)
Study: NCT04312269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
Study: NCT03710720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS app
Description: Psycho-educational electronic application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Focused-Cognitive Behavioral Therapy
Description: Effective form of trauma therapy for adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused-Cognitive Behavioral Therapy
Description: Effective form of trauma therapy for adolescents
Study: NCT01731795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
Study: NCT02935192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline, 0.5 mL by IM injection
Study: NCT05353686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XEN-D0501
Description: Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
Study: NCT01206517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg
Description: Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg
Description: Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg
Description: Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
Study: NCT01775527

Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Study: NCT02164526

Intervention type: OTHER
Intervention: Routine therapy
Description: Routine therapy
Study: NCT01973868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Study: NCT00258401

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
Study: NCT03453918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenols
Description: After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.
Study: NCT01973868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (ERBITUX)
Study: NCT03453918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.
Study: NCT00661830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg bid orally continuously
Study: NCT04152486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccine
Description: Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV.
Study: NCT01370876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
Study: NCT00305877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT00258401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
Study: NCT00305877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT04248998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq
Study: NCT00305877

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00305877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01294475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planned Activities Training
Description: Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
Study: NCT00066053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment: SRP
Description: Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Referral
Study: NCT02946346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal sampling
Study: NCT03925363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity mobile-application
Description: The active group will be given the feedback app and the control group the blind app

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Physical activity mobile-application
Description: The active group will be given the feedback app and the control group the blind app
Study: NCT00776529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training first, followed by strength exercises
Description: nine sessions of one hour duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercises and sensorimotor exercises alternated
Description: nine sessions of one hour
Study: NCT03991910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 5Mg Oral Capsule
Description: the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
Study: NCT02013375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Transplant
Description: All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: A 300cGy dose of TBI will be administered in a single fraction on Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
Study: NCT04485845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril Tablets
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril Tablets
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
Study: NCT01997645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAF
Study: NCT02580877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67.5 mg oral insulin crystals daily
Description: human insulin crystals in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg oral insulin crystals every other week
Description: human insulin crystals in capsules
Study: NCT00980148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: FDA approved, a 1 gm single dose, two 500 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: FDA approved, a 100 mg capsule twice a day for 7 days.
Study: NCT02973997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02268110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Supervised exercise therapy with a 12 week progressive abdominal exercise home program for

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Supervised exercise therapy with a 12 week progressive abdominal exercise home program for

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal binding
Description: Wearing an abdominal binder for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal binding
Description: Wearing an abdominal binder for 12 weeks
Study: NCT00284180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Novel second generation vinca alkaloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Novel second generation vinca alkaloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Anti-HER2 monoclonal antibody
Study: NCT00041340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04263844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Midazolam
Description: subject will receive premedication with intranasal midazolam thirty minutes before induction
Study: NCT05140356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applied high amplitude repeated transcranial magnetic stimulation
Description: Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applied low amplitude repeated transcranial magnetic stimulation
Description: Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
Study: NCT03795649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Imunomodulatory effect

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid
Description: Imunomodulatory effect
Study: NCT02013375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
Study: NCT03795649

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid
Description: Imunomodulatory effect
Study: NCT00595257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)
Description: autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)
Description: autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
Study: NCT04010097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: The test involves chewing a chewing gum for 4 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: The test involves chewing a chewing gum for 4 minutes
Study: NCT02449408

Intervention type: OTHER
Intervention: Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool

Intervention type: OTHER
Intervention: Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool
Study: NCT00987285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASM +
Description: Computer Assisted Self Management plus Social Support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASM
Description: Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
Study: NCT02468622

Intervention type: OTHER
Intervention: Blood samples
Description: There is no intervention, but we will take blood samples during a spontaneous migraine attack

Intervention type: OTHER
Intervention: Blood samples
Description: There is no intervention, but we will take blood samples during a spontaneous migraine attack
Study: NCT02158611

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle counseling
Study: NCT04218500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide 4%
Description: cream moisturizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virgin Coconut oil 30%
Description: cream moisturizer
Study: NCT01708590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered subcutaneous (SC)
Study: NCT04610983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Control
Description: 2 x algal oil gel capsules delivering 400mg DHA in total

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 1 - Semi-Solid food matrix
Description: Test Food 1: 200g serve soup + ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2 - Solid food matrix
Description: Test Food 2: 50g serve extruded snack (savoury snack) + ingredient
Study: NCT00593060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
Study: NCT02849002

Intervention type: DEVICE
Intervention: BrainPulse
Description: Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.